{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,18]],"date-time":"2026-03-18T16:03:58Z","timestamp":1773849838042,"version":"3.50.1"},"reference-count":54,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2024,6,1]],"date-time":"2024-06-01T00:00:00Z","timestamp":1717200000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,6,1]],"date-time":"2024-06-01T00:00:00Z","timestamp":1717200000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,4,29]],"date-time":"2024-04-29T00:00:00Z","timestamp":1714348800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100000925","name":"NHMRC","doi-asserted-by":"publisher","award":["APP1135949"],"award-info":[{"award-number":["APP1135949"]}],"id":[{"id":"10.13039\/501100000925","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004267","name":"Royal Adelaide Hospital","doi-asserted-by":"publisher","award":["APP1138935"],"award-info":[{"award-number":["APP1138935"]}],"id":[{"id":"10.13039\/501100004267","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004267","name":"Royal Adelaide Hospital","doi-asserted-by":"publisher","award":["APP1117718"],"award-info":[{"award-number":["APP1117718"]}],"id":[{"id":"10.13039\/501100004267","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004267","name":"Royal Adelaide Hospital","doi-asserted-by":"publisher","award":["APP1027531"],"award-info":[{"award-number":["APP1027531"]}],"id":[{"id":"10.13039\/501100004267","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100014152","name":"Ray and Shirl Norman Cancer Research Trust","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100014152","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100020670","name":"Cancer Council Australia","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100020670","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Blood Neoplasia"],"published-print":{"date-parts":[[2024,6]]},"DOI":"10.1016\/j.bneo.2024.100014","type":"journal-article","created":{"date-parts":[[2024,4,30]],"date-time":"2024-04-30T06:10:26Z","timestamp":1714457426000},"page":"100014","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"title":["CD302 predicts achievement of deep molecular response in patients with chronic myeloid leukemia treated with imatinib"],"prefix":"10.1016","volume":"1","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-3181-7852","authenticated-orcid":false,"given":"Chung Hoow","family":"Kok","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2861-5774","authenticated-orcid":false,"given":"Yazad","family":"Irani","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jade","family":"Clarson","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Verity","family":"Saunders","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Phuong","family":"Dang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5895-8797","authenticated-orcid":false,"given":"Naranie","family":"Shanmuganathan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5095-7981","authenticated-orcid":false,"given":"Susan","family":"Branford","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7558-9927","authenticated-orcid":false,"given":"David","family":"Yeung","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Agnes S. M.","family":"Yong","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Timothy P.","family":"Hughes","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"5","key":"10.1016\/j.bneo.2024.100014_bib1","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1200\/JCO.2013.49.9020","article-title":"Deep molecular response is reached by the majority of patients treated with imatinib, predicts survival, and is achieved more quickly by optimized high-dose imatinib: results from the randomized CML-study IV","volume":"32","author":"Hehlmann","year":"2014","journal-title":"J\u00a0Clin Oncol"},{"issue":"3","key":"10.1016\/j.bneo.2024.100014_bib2","doi-asserted-by":"crossref","first-page":"232","DOI":"10.1200\/JCO.2011.38.6565","article-title":"Assessment of BCR-ABL1 transcript levels at 3\u00a0months is the only requirement for predicting outcome for patients with chronic myeloid leukemia treated with tyrosine kinase inhibitors","volume":"30","author":"Marin","year":"2012","journal-title":"J\u00a0Clin Oncol"},{"issue":"4","key":"10.1016\/j.bneo.2024.100014_bib3","doi-asserted-by":"crossref","first-page":"511","DOI":"10.1182\/blood-2014-03-566323","article-title":"Prognosis for patients with CML and >10% BCR-ABL1 after 3\u00a0months of imatinib depends on the rate of BCR-ABL1 decline","volume":"124","author":"Branford","year":"2014","journal-title":"Blood"},{"issue":"4","key":"10.1016\/j.bneo.2024.100014_bib4","doi-asserted-by":"crossref","first-page":"966","DOI":"10.1038\/s41375-020-0776-2","article-title":"European LeukemiaNet 2020 recommendations for treating chronic myeloid leukemia","volume":"34","author":"Hochhaus","year":"2020","journal-title":"Leukemia"},{"issue":"9","key":"10.1016\/j.bneo.2024.100014_bib5","doi-asserted-by":"crossref","first-page":"1166","DOI":"10.1182\/blood-2016-10-745992","article-title":"CML patients with deep molecular responses to TKI have restored immune effectors and decreased PD-1 and immune suppressors","volume":"129","author":"Hughes","year":"2017","journal-title":"Blood"},{"issue":"11","key":"10.1016\/j.bneo.2024.100014_bib6","doi-asserted-by":"crossref","first-page":"2223","DOI":"10.1007\/s00262-020-02617-5","article-title":"Differences in PD-1 expression on CD8+ T-cells in chronic myeloid leukemia patients according to disease phase and TKI medication","volume":"69","author":"Lee","year":"2020","journal-title":"Cancer Immunol Immunother"},{"issue":"22","key":"10.1016\/j.bneo.2024.100014_bib7","first-page":"2738","article-title":"A\u00a0single-cell atlas identifies pretreatment features of primary imatinib resistance in chronic myeloid leukemia","volume":"141","author":"Krishnan","year":"2023","journal-title":"Blood"},{"issue":"6","key":"10.1016\/j.bneo.2024.100014_bib8","doi-asserted-by":"crossref","first-page":"915","DOI":"10.1182\/blood-2014-07-590315","article-title":"TIDEL-II: first-line use of imatinib in CML with early switch to nilotinib for failure to achieve time-dependent molecular targets","volume":"125","author":"Yeung","year":"2015","journal-title":"Blood"},{"issue":"6","key":"10.1016\/j.bneo.2024.100014_bib9","doi-asserted-by":"crossref","first-page":"872","DOI":"10.1182\/blood-2013-05-501569","article-title":"European LeukemiaNet recommendations for the management of chronic myeloid leukemia: 2013","volume":"122","author":"Baccarani","year":"2013","journal-title":"Blood"},{"issue":"2","key":"10.1016\/j.bneo.2024.100014_bib10","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1111\/bjh.14829","article-title":"Nilotinib dose-optimization in newly diagnosed chronic myeloid leukaemia in chronic phase: final results from ENESTxtnd","volume":"179","author":"Hughes","year":"2017","journal-title":"Br J Haematol"},{"key":"10.1016\/j.bneo.2024.100014_bib11","doi-asserted-by":"crossref","first-page":"4150","DOI":"10.1182\/blood-2019-127619","article-title":"Pro-active dasatinib dose reduction based on trough levels may minimise toxicity and preserve efficacy - interim analysis of the ALLG CML 12 Direct Study","volume":"134","author":"Yeung","year":"2019","journal-title":"Blood"},{"key":"10.1016\/j.bneo.2024.100014_bib12","doi-asserted-by":"crossref","first-page":"615","DOI":"10.1097\/01.HS9.0000845764.61186.15","article-title":"P720: proactive dasatinib dose reduction in the ALLG CML 12 direct study based on trough levels minimise toxicity and preserve efficacy","volume":"6","author":"Yeung","year":"2022","journal-title":"HemaSphere"},{"issue":"10","key":"10.1016\/j.bneo.2024.100014_bib13","doi-asserted-by":"crossref","first-page":"1610","DOI":"10.1182\/bloodadvances.2019000195","article-title":"Gene expression signature that predicts early molecular response failure in chronic-phase CML patients on frontline imatinib","volume":"3","author":"Kok","year":"2019","journal-title":"Blood Adv"},{"issue":"D1","key":"10.1016\/j.bneo.2024.100014_bib14","doi-asserted-by":"crossref","first-page":"D1003","DOI":"10.1093\/nar\/gkac888","article-title":"Genenames.org: the HGNC resources in 2023","volume":"51","author":"Seal","year":"2023","journal-title":"Nucleic Acids Res"},{"issue":"11","key":"10.1016\/j.bneo.2024.100014_bib15","doi-asserted-by":"crossref","first-page":"2364","DOI":"10.1182\/bloodadvances.2022008854","article-title":"Association of TIM-3 checkpoint receptor expression on T cells with treatment-free remission in chronic myeloid leukemia","volume":"7","author":"Irani","year":"2023","journal-title":"Blood Adv"},{"issue":"3","key":"10.1016\/j.bneo.2024.100014_bib16","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1111\/bjh.16718","article-title":"Successful treatment-free remission in chronic myeloid leukaemia and its association with reduced immune suppressors and increased natural killer cells","volume":"191","author":"Irani","year":"2020","journal-title":"Br J Haematol"},{"issue":"6","key":"10.1016\/j.bneo.2024.100014_bib17","doi-asserted-by":"crossref","first-page":"1127","DOI":"10.1111\/bjh.18984","article-title":"Immune modulation in chronic myeloid leukaemia patients treated with nilotinib and interferon-alpha","volume":"202","author":"Irani","year":"2023","journal-title":"Br J Haematol"},{"issue":"6","key":"10.1016\/j.bneo.2024.100014_bib18","doi-asserted-by":"crossref","first-page":"1263","DOI":"10.1038\/leu.2016.34","article-title":"TGF-alpha and IL-6 plasma levels selectively identify CML patients who fail to achieve an early molecular response or progress in the first year of therapy","volume":"30","author":"Nievergall","year":"2016","journal-title":"Leukemia"},{"issue":"25","key":"10.1016\/j.bneo.2024.100014_bib19","doi-asserted-by":"crossref","first-page":"2720","DOI":"10.1182\/blood-2015-07-655589","article-title":"KIR2DL5B genotype predicts outcomes in CML patients treated with response-directed sequential imatinib\/nilotinib strategy","volume":"126","author":"Yeung","year":"2015","journal-title":"Blood"},{"issue":"18","key":"10.1016\/j.bneo.2024.100014_bib20","doi-asserted-by":"crossref","first-page":"1369","DOI":"10.1182\/bloodadvances.2017006825","article-title":"ASXL1 and BIM germ line variants predict response and identify CML patients with the greatest risk of imatinib failure","volume":"1","author":"Marum","year":"2017","journal-title":"Blood Adv"},{"issue":"6","key":"10.1016\/j.bneo.2024.100014_bib21","doi-asserted-by":"crossref","first-page":"907","DOI":"10.3324\/haematol.2011.056457","article-title":"Chronic phase chronic myeloid leukemia patients with low OCT-1 activity randomized to high-dose imatinib achieve better responses and have lower failure rates than those randomized to standard-dose imatinib","volume":"97","author":"White","year":"2012","journal-title":"Haematologica"},{"issue":"16","key":"10.1016\/j.bneo.2024.100014_bib22","doi-asserted-by":"crossref","first-page":"2761","DOI":"10.1200\/JCO.2009.26.5819","article-title":"Functional activity of the OCT-1 protein is predictive of long-term outcome in patients with chronic-phase chronic myeloid leukemia treated with imatinib","volume":"28","author":"White","year":"2010","journal-title":"J\u00a0Clin Oncol"},{"issue":"1","key":"10.1016\/j.bneo.2024.100014_bib23","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1038\/leu.2016.179","article-title":"The clinical significance of ABCB1 overexpression in predicting outcome of CML patients undergoing first-line imatinib treatment","volume":"31","author":"Eadie","year":"2017","journal-title":"Leukemia"},{"issue":"9","key":"10.1016\/j.bneo.2024.100014_bib24","doi-asserted-by":"crossref","first-page":"1196","DOI":"10.1182\/blood.2020005514","article-title":"Early BCR-ABL1 kinetics are predictive of subsequent achievement of treatment-free remission in chronic myeloid leukemia","volume":"137","author":"Shanmuganathan","year":"2021","journal-title":"Blood"},{"issue":"5","key":"10.1016\/j.bneo.2024.100014_bib25","doi-asserted-by":"crossref","first-page":"1159","DOI":"10.1007\/s00277-019-03633-x","article-title":"Impact of second decline rate of BCR-ABL1 transcript on clinical outcome of chronic phase chronic myeloid leukemia patients on imatinib first-line","volume":"98","author":"Dulucq","year":"2019","journal-title":"Ann Hematol"},{"issue":"1","key":"10.1016\/j.bneo.2024.100014_bib26","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1038\/s41408-023-00917-4","article-title":"Adverse outcomes for chronic myeloid leukemia patients with splenomegaly and low in\u00a0vivo kinase inhibition on imatinib","volume":"13","author":"Kok","year":"2023","journal-title":"Blood Cancer J"},{"issue":"4","key":"10.1016\/j.bneo.2024.100014_bib27","doi-asserted-by":"crossref","first-page":"789","DOI":"10.1182\/blood.V63.4.789.789","article-title":"Prognostic discrimination in \"good-risk\" chronic granulocytic leukemia","volume":"63","author":"Sokal","year":"1984","journal-title":"Blood"},{"issue":"1","key":"10.1016\/j.bneo.2024.100014_bib28","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1038\/leu.2015.261","article-title":"Prognosis of long-term survival considering disease-specific death in patients with chronic myeloid leukemia","volume":"30","author":"Pfirrmann","year":"2016","journal-title":"Leukemia"},{"issue":"9","key":"10.1016\/j.bneo.2024.100014_bib29","doi-asserted-by":"crossref","first-page":"1441","DOI":"10.3324\/haematol.2013.096537","article-title":"Distinct characteristics of e13a2 versus e14a2 BCR-ABL1 driven chronic myeloid leukemia under first-line therapy with imatinib","volume":"99","author":"Hanfstein","year":"2014","journal-title":"Haematologica"},{"issue":"10","key":"10.1016\/j.bneo.2024.100014_bib30","doi-asserted-by":"crossref","first-page":"1362","DOI":"10.3324\/haematol.2009.009134","article-title":"Chronic myeloid leukemia patients with the e13a2 BCR-ABL fusion transcript have inferior responses to imatinib compared to patients with the e14a2 transcript","volume":"94","author":"Lucas","year":"2009","journal-title":"Haematologica"},{"key":"10.1016\/j.bneo.2024.100014_bib31","doi-asserted-by":"crossref","DOI":"10.1111\/cas.15501","article-title":"Comparison of molecular responses and outcomes between BCR::ABL1 e14a2 and e13a2 transcripts in chronic myeloid leukemia","author":"Su","year":"2022","journal-title":"Cancer Sci"},{"issue":"10","key":"10.1016\/j.bneo.2024.100014_bib32","doi-asserted-by":"crossref","first-page":"1988","DOI":"10.1038\/leu.2014.153","article-title":"Velocity of early BCR-ABL transcript elimination as an optimized predictor of outcome in chronic myeloid leukemia (CML) patients in chronic phase on treatment with imatinib","volume":"28","author":"Hanfstein","year":"2014","journal-title":"Leukemia"},{"issue":"43","key":"10.1016\/j.bneo.2024.100014_bib33","doi-asserted-by":"crossref","first-page":"15545","DOI":"10.1073\/pnas.0506580102","article-title":"Gene set enrichment analysis: a knowledge-based approach for interpreting genome-wide expression profiles","volume":"102","author":"Subramanian","year":"2005","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"6","key":"10.1016\/j.bneo.2024.100014_bib34","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1016\/j.cels.2015.12.004","article-title":"The Molecular Signatures Database (MSigDB) hallmark gene set collection","volume":"1","author":"Liberzon","year":"2015","journal-title":"Cell Syst"},{"issue":"3","key":"10.1016\/j.bneo.2024.100014_bib35","doi-asserted-by":"crossref","first-page":"294","DOI":"10.1038\/clpt.2013.208","article-title":"Interaction of the efflux transporters ABCB1 and ABCG2 with imatinib, nilotinib, and dasatinib","volume":"95","author":"Eadie","year":"2014","journal-title":"Clin Pharmacol Ther"},{"issue":"2","key":"10.1016\/j.bneo.2024.100014_bib36","doi-asserted-by":"crossref","first-page":"697","DOI":"10.1182\/blood-2005-11-4687","article-title":"OCT-1-mediated influx is a key determinant of the intracellular uptake of imatinib but not nilotinib (AMN107): reduced OCT-1 activity is the cause of low in\u00a0vitro sensitivity to imatinib","volume":"108","author":"White","year":"2006","journal-title":"Blood"},{"issue":"8","key":"10.1016\/j.bneo.2024.100014_bib37","doi-asserted-by":"crossref","first-page":"3496","DOI":"10.1182\/blood-2006-07-036012","article-title":"Trough imatinib plasma levels are associated with both cytogenetic and molecular responses to standard-dose imatinib in chronic myeloid leukemia","volume":"109","author":"Picard","year":"2007","journal-title":"Blood"},{"issue":"12","key":"10.1016\/j.bneo.2024.100014_bib38","doi-asserted-by":"crossref","first-page":"2730","DOI":"10.3324\/haematol.2019.240739","article-title":"Why is it critical to achieve a deep molecular response in chronic myeloid leukemia?","volume":"105","author":"Branford","year":"2020","journal-title":"Haematologica"},{"issue":"6","key":"10.1016\/j.bneo.2024.100014_bib39","doi-asserted-by":"crossref","first-page":"683","DOI":"10.1007\/s12185-019-02744-5","article-title":"Effect of study-level factors on treatment-free remission rate in patients with chronic myeloid leukemia: a systematic review and meta-analysis","volume":"110","author":"Kim","year":"2019","journal-title":"Int J Hematol"},{"issue":"19","key":"10.1016\/j.bneo.2024.100014_bib40","doi-asserted-by":"crossref","first-page":"3818","DOI":"10.1182\/blood-2012-10-462291","article-title":"Early molecular response and female sex strongly predict stable undetectable BCR-ABL1, the criteria for imatinib discontinuation in patients with CML","volume":"121","author":"Branford","year":"2013","journal-title":"Blood"},{"issue":"2","key":"10.1016\/j.bneo.2024.100014_bib41","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1182\/blood-2009-03-210732","article-title":"A\u00a0gene expression signature of CD34+ cells to predict major cytogenetic response in chronic-phase chronic myeloid leukemia patients treated with imatinib","volume":"115","author":"McWeeney","year":"2010","journal-title":"Blood"},{"issue":"1","key":"10.1016\/j.bneo.2024.100014_bib42","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1182\/blood-2005-05-2155","article-title":"Molecular profiling of CD34+ cells identifies low expression of CD7, along with high expression of proteinase 3 or elastase, as predictors of longer survival in patients with CML","volume":"107","author":"Yong","year":"2006","journal-title":"Blood"},{"issue":"4","key":"10.1016\/j.bneo.2024.100014_bib43","first-page":"459","article-title":"In chronic myeloid leukemia white cells from cytogenetic responders and non-responders to imatinib have very similar gene expression signatures","volume":"90","author":"Crossman","year":"2005","journal-title":"Haematologica"},{"issue":"5","key":"10.1016\/j.bneo.2024.100014_bib44","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0216368","article-title":"Examination of CD302 as a potential therapeutic target for acute myeloid leukemia","volume":"14","author":"Lo","year":"2019","journal-title":"PLoS One"},{"key":"10.1016\/j.bneo.2024.100014_bib45","doi-asserted-by":"crossref","first-page":"289","DOI":"10.3389\/fimmu.2012.00289","article-title":"KIR2DL5: an orphan inhibitory receptor displaying complex patterns of polymorphism and expression","volume":"3","author":"Cisneros","year":"2012","journal-title":"Front Immunol"},{"issue":"7","key":"10.1016\/j.bneo.2024.100014_bib46","doi-asserted-by":"crossref","first-page":"4402","DOI":"10.4049\/jimmunol.178.7.4402","article-title":"Human KIR2DL5 is an inhibitory receptor expressed on the surface of NK and T lymphocyte subsets","volume":"178","author":"Estefania","year":"2007","journal-title":"J\u00a0Immunol"},{"issue":"11","key":"10.1016\/j.bneo.2024.100014_bib47","doi-asserted-by":"crossref","first-page":"906","DOI":"10.1016\/j.exphem.2012.07.007","article-title":"Killer-cell immunoglobulin-like receptor gene profile predicts good molecular response to dasatinib therapy in chronic myeloid leukemia","volume":"40","author":"Kreutzman","year":"2012","journal-title":"Exp Hematol"},{"issue":"2","key":"10.1016\/j.bneo.2024.100014_bib48","doi-asserted-by":"crossref","first-page":"296","DOI":"10.1038\/leu.2011.180","article-title":"KIR2DS1 genotype predicts for complete cytogenetic response and survival in newly diagnosed chronic myeloid leukemia patients treated with imatinib","volume":"26","author":"Marin","year":"2012","journal-title":"Leukemia"},{"issue":"11","key":"10.1016\/j.bneo.2024.100014_bib49","doi-asserted-by":"crossref","first-page":"4976","DOI":"10.1002\/cam4.2371","article-title":"Killer immunoglobulin-like receptor genotypes and chronic myeloid leukemia outcomes after imatinib cessation for treatment-free remission","volume":"8","author":"Dumas","year":"2019","journal-title":"Cancer Med"},{"issue":"2","key":"10.1016\/j.bneo.2024.100014_bib50","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1200\/JCO.2016.67.0893","article-title":"Reduced CD62L expression on T cells and increased soluble CD62L levels predict molecular response to tyrosine kinase inhibitor therapy in early chronic-phase chronic myelogenous leukemia","volume":"35","author":"Sopper","year":"2017","journal-title":"J\u00a0Clin Oncol"},{"issue":"8","key":"10.1016\/j.bneo.2024.100014_bib51","doi-asserted-by":"crossref","first-page":"1964","DOI":"10.1038\/s41375-019-0427-7","article-title":"Stem cell persistence in CML is mediated by extrinsically activated JAK1-STAT3 signaling","volume":"33","author":"Kuepper","year":"2019","journal-title":"Leukemia"},{"issue":"12","key":"10.1016\/j.bneo.2024.100014_bib52","doi-asserted-by":"crossref","first-page":"3371","DOI":"10.1038\/s41375-021-01315-0","article-title":"Metabolic alterations mediated by STAT3 promotes drug persistence in CML","volume":"35","author":"Patel","year":"2021","journal-title":"Leukemia"},{"issue":"1","key":"10.1016\/j.bneo.2024.100014_bib53","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1038\/s41420-023-01700-x","article-title":"AMPK-induced novel phosphorylation of RUNX1 inhibits STAT3 activation and overcome imatinib resistance in chronic myelogenous leukemia (CML) subjects","volume":"9","author":"Gayatri","year":"2023","journal-title":"Cell Death Discov"},{"issue":"3","key":"10.1016\/j.bneo.2024.100014_bib54","doi-asserted-by":"crossref","first-page":"586","DOI":"10.1038\/leu.2014.245","article-title":"Combined STAT3 and BCR-ABL1 inhibition induces synthetic lethality in therapy-resistant chronic myeloid leukemia","volume":"29","author":"Eiring","year":"2015","journal-title":"Leukemia"}],"container-title":["Blood Neoplasia"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2950328024000141?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2950328024000141?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,9]],"date-time":"2025-11-09T02:58:24Z","timestamp":1762657104000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2950328024000141"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,6]]},"references-count":54,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2024,6]]}},"alternative-id":["S2950328024000141"],"URL":"https:\/\/doi.org\/10.1016\/j.bneo.2024.100014","relation":{},"ISSN":["2950-3280"],"issn-type":[{"value":"2950-3280","type":"print"}],"subject":[],"published":{"date-parts":[[2024,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"CD302 predicts achievement of deep molecular response in patients with chronic myeloid leukemia treated with imatinib","name":"articletitle","label":"Article Title"},{"value":"Blood Neoplasia","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.bneo.2024.100014","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 by The American Society of Hematology. Licensed under Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0), permitting only noncommercial, nonderivative use with attribution. All other rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"100014"}}